Ripple Therapeutics Wins the 2026 Gold Leaf Award for Promising Biotech Company of the Year

Congratulations to Ripple Therapeutics for taking home BIOTECanada’s 2026 Gold Leaf Award for Promising Biotech Company of the Year! This award celebrates small and mid-sized pre-commercial companies that distinguish themselves through innovation, strategic milestones, and strong growth potential. Ripple’s well-deserved recognition reflects their innovative sustained drug delivery platform, incredible clinical momentum, and key partnerships. Thrilled to see them paving the way for better patient care and solidifying their status as a leading Canadian ophthalmology company.

Ripple Therapeutics is an OBIO® member, an alumnus of our BDSP™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.